LITIG Equity Partners and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association held “Global IP Strategy Forum for Bio-Pharma” on October 27 in the 4th-floor auditorium of the Pharmaceutical Association Building in Seoul.

The forum has been organized in response to the rapid globalization of the bio-pharmaceutical industry, as intellectual property (IP) issues such as overseas licensing agreements, M&A, investment, and patent disputes have emerged as key factors in corporate competitiveness. Through this event, the Association aims to strengthen the IP risk management capabilities of Korean bio-pharmaceutical companies and explore practical strategies for addressing these challenges.

As the importance of end-to-end IP management grows—from early-stage drug development and IP strategy formulation to contractual issues, dispute resolution, and financing—the forum will serve as a venue for discussing practical solutions based on domestic and international case studies.

The program opened with Patent Attorney Yoon Sun-young of Kim & Chang presenting on “Practical IP Issues in Overseas Licensing Agreements,” introducing key clause design strategies based on real contract examples. Attorney Choi Sang-kyun, also from Kim & Chang, followed with a session on “Essential IP Management Strategies in Overseas M&A and Investments,” covering IP rights succession procedures and due diligence checklists.

Patent Attorney Yoon Kyung-ae of Yulchon LLC delivered a presentation on “Building an IP Portfolio and Patent Dispute Strategies for Global Expansion,” analyzing major global patent dispute types and case-specific response strategies. Attorney Tae Hun Lee of LITIG Equity Partners introduced the use of Third Party Funding (TPF) as a tool for Korean companies to manage the financial and procedural risks they face in overseas disputes.

A panel discussion followed under the theme “IP Strategies and Challenges for Korean Companies in the Global Bio-Pharma Market.” The discussion was chaired by Professor Joon-Hyug Chung of Seoul National University School of Law and featured panelists from Kim & Chang, Yulchon LLC, LITIG Equity Partners, Yuhan Corporation, and OMNI Bridgeway, a leading global TPF funding group. The panel discussed Korean companies’ experiences in managing IP risks during overseas co-development projects, as well as case studies of TPF utilization in the global bio-pharma sector, exploring diverse approaches to building effective global IP strategies.